Relationship between thrombospondin-1 and the occurrence and development of oral and maxillofacial malignancy

doi:10.7518/hxkq.2018.06.020

Abstract

Abstract:

Thrombospondin-1 (TSP-1) is widely distributed in human tissues and is important in inhibiting angiogenesis.It also occupies an indispensable position in the formation, growth, differentiation, and metastasis of tumors in different tissues.TSP-1 plays an important role in the occurrence and development of various types of tumors. The inhibitory effect of TSP-1 on the angiogenesis and tumor development of oral and maxillofacial malignant tumors has been demonstrated in recent years. This paper reviews the findings and progress of TSP-1 research involving all kinds of tumors as well as oral and maxillofacial malignancies.

Key words: oral and maxillofacial malignancy, thrombospondin-1, solid tumor, vascular suppression

CLC Number:

R739.8

Xueqin Zhou,Jun Ren,Sen Yang. Relationship between thrombospondin-1 and the occurrence and development of oral and maxillofacial malignancy[J]. West China Journal of Stomatology, 2018, 36(6): 686-690.

References 58

[1]	Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease[J]. Nat Med, 1995,1(1):27-30. doi: 10.1038/nm0195-27 URL pmid: 7584949
[2]	Weng TY, Huang SS, Yen MC , et al. A novel cancer thera-peutic using thrombospondin 1 in dendritic cells[J]. Mol Ther, 2014,22(2):292-302. doi: 10.1038/mt.2013.236 URL pmid: 24127010
[3]	张志愿, 俞光岩 . 口腔颌面外科学[M]. 7版. 北京: 人民卫生出版社, 2012: 281.
	Zhang ZY, Yu GY. Oral and maxillofacial surgery[M]. 7th ed. Beijing: People’s Medical Publishing House, 2012: 281.
[4]	Schadler KL, Crosby EJ, Zhou AY , et al. Immunosurveil-lance by antiangiogenesis: tumor growth arrest by T cell-derived thrombospondin-1[J]. Cancer Res, 2014,74(8):2171-2181. doi: 10.1158/0008-5472.CAN-13-0094 URL pmid: 8980132210002224590059
[5]	Amagasaki K, Sasaki A, Kato G , et al. Antisense-mediated reduction in thrombospondin-1 expression reduces cell moti-lity in malignant gliomacells[J]. Int J Cancer, 2001,94(4):508-512. doi: 10.1002/ijc.1497 URL
[6]	Grutzmacher C, Park S, Zhao Y , et al. Aberrant production of extracellular matrix proteins and dysfunction in kidney endothelial cells with a short duration of diabetes[J]. Am J Physiol Renal Physiol, 2013,304(1):F19-F30. doi: 10.1152/ajprenal.00036.2012 URL
[7]	Esemuede N, Lee T, Pierre-Paul D , et al. The role of throm-bospondin-1 in human disease1[J]. J Surg Res, 2004,122(1):135-142. doi: 10.1016/j.jss.2004.05.015 URL pmid: 15522326
[8]	Roberts DD . Thrombospondins: from structure to therapeu-tics[J]. Cell Mol Life Sci, 2008,65(5):669-671.
[9]	Adams JC . Thrombospondin-1[J]. Int J Biochem Cell Biol, 1997,29(6):861-865. doi: 10.1016/S1357-2725(96)00171-9 URL
[10]	Qian X, Tuszynski GP . Expression of thrombospondin-1 in cancer: a role in tumor progression[J]. Exp Biol Med, 1996,212(3):199-207. doi: 10.3181/00379727-212-44008 URL pmid: 8677265
[11]	Bornstein P . Thrombospondins: structure and regulation of expression[J]. FASEB, 1992,6(14):3290-3299. doi: 10.1016/0014-4827(92)90067-I URL pmid: 8422970
[12]	McCracken MN, Cha AC, Weissman IL . Molecular path-ways: activating T cells after cancer cell phagocytosis from blockade of CD47 “don’t eat me” signals[J]. Clin Cancer Res, 2015,21(16):3597-3601. doi: 10.1158/1078-0432.CCR-14-2520 URL pmid: 26116271
[13]	Jaiswal S, Chao MP, Majeti R , et al. Macrophages as media-tors of tumor immunosurveillance[J]. Trends Immunol, 2010,31(6):212-219. doi: 10.1016/j.it.2010.04.001 URL pmid: 20452821
[14]	Isenberg JS, Martin-Manso G, Maxhimer JB , et al. Regula-tion of nitric oxide signalling by thrombospondin 1: impli-cations for anti-angiogenictherapies[J]. Nat Rev Cancer, 2009,9(3):182-194. doi: 10.1038/nrc2561 URL pmid: 19194382
[15]	Ren B, Yee KO, Lawler J , et al. Regulation of tumor angio-genesis by thrombospondin-1[J]. Biochim Biophys Acta, 2006,1765(2):178-188.
[16]	Watnick RS, Rodriguez RK, Wang S , et al. Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells[J]. Oncogene, 2015,34(22):2823-2835. doi: 10.1038/onc.2014.228 URL pmid: 25109329
[17]	Miyata Y, Sakai H . Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic pros-pects[J]. Int J Mol Sci, 2013,14(6):12249-12272. doi: 10.3390/ijms140612249 URL pmid: 3709784
[18]	Yap R . Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin pep-tide ABT-510: a complementation antiangiogenic strategy[J]. Clin Cancer Res, 2005,11(18):6678-6685. doi: 10.1158/1078-0432.CCR-05-0621 URL pmid: 16166447
[19]	Tao WY, Liang XS, Liu Y , et al. Decrease of let-7f in low-dose metronomic paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer[J]. Int J Biol Sci, 2015,11(1):48-58. doi: 10.7150/ijbs.9969 URL pmid: 25552929
[20]	Rodriguez-Manzaneque JC, Lane TF, Ortega MA , et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor[J]. Proc Natl Acad Sci USA, 2001,98(22):12485-12490. doi: 10.1073/pnas.171460498 URL
[21]	Fontana A, Filleur S, Guglielmi J , et al. Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo[J]. Int J Cancer, 2005,116(5):686-691. doi: 10.1002/ijc.20584 URL pmid: 15838828
[22]	Rice AJ . Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast[J]. J Clin Pathol, 2002,55(12):921-925. doi: 10.1136/jcp.55.12.921 URL pmid: 539294
[23]	Wang XJ, Yu JJ, Sreekumar A , et al. Autoantibody signatures in prostate cancer[J]. N Engl J Med, 2005,353(12):1224-1235. doi: 10.1016/j.eururo.2005.12.066 URL pmid: 16177248
[24]	Dhanasekaran SM, Barrette TR, Ghosh D , et al. Delineation of prognostic biomarkers in prostate cancer[J]. Nature, 2001,412(6849):822-826.
[25]	Luo J, Duggan DJ, Chen Y , et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling[J]. Cancer Res, 2001,61(12):4683-4688.
[26]	Bastian M, Steiner M, Schuff-Werner P . Expression of throm-bospondin-1 in prostate-derived cell lines[J]. Int J Mol Med, 2005,15(1):49-56.
[27]	Gustavsson H, Tesan T, Jennbacken K , et al. ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors[J]. BMC Cancer, 2010,10:288. doi: 10.1186/1471-2407-10-288 URL pmid: 2894797
[28]	Firlej V, Mathieu JR, Gilbert C , et al. Thrombospondin-1 triggers cell migration and development of advanced prostate tumors[J]. Cancer Res, 2011,71(24):7649-7658. doi: 10.1158/0008-5472.CAN-11-0833 URL pmid: 22037878
[29]	Yang F, Song L, Xing N , et al. AB170. Quercetin inhibits angiogenesis through thrombospondin-1 up-regulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo[J]. Oncol Rep, 2016,5(Suppl 1):1602-1610. doi: 10.21037/tau.2016.s170 URL pmid: 26676551
[30]	Rouanne M, Adam J, Goubar A , et al. Osteopontin and throm-bospondin-1 play opposite roles in promoting tumor aggres-siveness of primary resected non-small cell lung cancer[J]. BMC Cancer, 2016,16:483. doi: 10.1186/s12885-016-2541-5 URL pmid: 4947364
[31]	Yamaguchi M, Sugio K, Ondo K , et al. Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer[J]. Lung Cancer, 2002,36(2):143-150. doi: 10.1016/S0169-5002(01)00470-6 URL pmid: 11955648
[32]	Fleitas T, Martínez-Sales V, Vila V , et al. VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer[J]. Clin Transl Oncol, 2013,15(11):897-902. doi: 10.1007/s12094-013-1020-6 URL pmid: 23463593
[33]	Puri N, Pitman RT, Mulnix RE , et al. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oli-gonucleotides[J]. Cancer Lett, 2014,343(1):14-23. doi: 10.1016/j.canlet.2013.09.010 URL pmid: 24041868
[34]	Laklai H, Laval S, Dumartin L , et al. Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 soma-tostatin receptor on pancreatic cancer[J]. Proc Natl Acad Sci USA, 2009,106(42):17769-17774. doi: 10.1073/pnas.0908674106 URL pmid: 19805200
[35]	Kragh M, Quistorff B, Tenan M , et al. Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma[J]. Cancer Res, 2002,62(4):1191-1195.
[36]	Zhang J, Yang W, Zhao DY , et al. Correlation between TSP-1, TGF-β and PPAR-γ expression levels and gliomamicrovasculardensity[J]. Oncol Let, 2014,7(1):95-100. doi: 10.3892/ol.2013.1650 URL pmid: 3861559
[37]	Gaustad JV, Simonsen TG, Andersen LMK , et al. Throm-bospondin-1 domain-containing peptide properdistatin im-proves vascular function in human melanoma xenografts[J]. Microvasc Res, 2015,98:159-165. doi: 10.1016/j.mvr.2014.02.005 URL
[38]	Bocci G, Fioravanti A, Orlandi P , et al. Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclinD1[J]. Neoplasia, 2012,14(9):833-845. doi: 10.1593/neo.12772 URL pmid: 3459279
[39]	Pour L, Svachova H, Adam Z , et al. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma[J]. Neo-plasma, 2010,57(1):29-34. doi: 10.4149/neo_2010_01_029 URL pmid: 19895169
[40]	Hayashido Y, Nakashima M, Urabe K , et al. Role of stromal thrombospondin-1 in motility and proteolytic activity of oral squamous cell carcinoma cells[J]. Int J Mol Med, 2003,12(4):447-452. doi: 10.3892/ijmm.12.4.447 URL pmid: 12964017
[41]	Yao L, Zhao YL, Itoh S , et al. Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival[J]. Oral Oncol, 2000,36(6):539-544. doi: 10.1016/S1368-8375(00)00048-8 URL pmid: 11036248
[42]	杨森, 唐休发, 郭丽娟 , 等. 黏液表皮样癌中TSP-1表达与肿瘤血管生成及其生物学行为的关系研究[J]. 四川大学学报(医学版), 2008,39(5):763-765. doi: 10.3969/j.issn.1672-173X.2008.05.016 URL
	Yang S, Tang XF, Guo LJ , et al. Correlation between the expression of thrombospondin-1 and the angiogenesis in mucoepidermoid carcinoma[J]. J Sichuan Univ (Med Sci Ed), 2008,39(5):763-765. doi: 10.3969/j.issn.1672-173X.2008.05.016 URL
[43]	Yang S, Wang XY, Guo LJ , et al. Correlation between the expression of thrombospondin-1 and neovascularization in mucoepidermoid carcinoma[J]. Chin Med J, 2008,121(19):1875-1881. doi: 10.1016/j.ijom.2009.03.483 URL pmid: 19080117
[44]	杨森, 李安, 郭丽娟 , 等. 唾液腺黏液表皮样癌组织中分化抑制因子-1和血小板反应蛋白-1的表达[J]. 华西口腔医学杂志, 2008,26(4):425-429.
	Yang S, Li A, Guo LJ , et al. The expression of inhibitor-1 of DNA binding/differentiation-1 and thrombospondin-1 in mucoepidermoid carcinoma of different malignant degree[J]. West Chin J Stomatol, 2008,26(4):425-429.
[45]	Yang S, Guo LJ, Tang XF , et al. The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis[J]. Int J Oral Maxil-lofac Surg, 2010,39(1):29-35. doi: 10.1016/j.ijom.2009.10.004 URL pmid: 19906510
[46]	龚仁国 . Id-1和TSP-1在唾液腺腺样囊性癌中的表达及意义[D]. 成都: 四川大学, 2007.
	Gong RG . Expression and significance of Id-1 and TSP-1 in human adenoid cystic carcinoma[D]. Chengdu: Sichuan University, 2007.
[47]	Qian X, Tuszynski GP . Expression of thrombospondin-1 in cancer: a role in tumor progression[J]. Exp Biol Med, 1996,212(3):199-207. doi: 10.3181/00379727-212-44008 URL pmid: 8677265
[48]	Kaur S, Roberts DD . Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 sig-naling[J]. Int J Biochem Cell Biol, 2016,81(Pt A):184-194. doi: 10.1016/j.biocel.2016.05.005 URL pmid: 27163531
[49]	Denèfle T, Boullet H, Herbi L , et al. Thrombospondin-1 mimetic agonist peptides induce selective death in tumor cells: design, synjournal, and structure-activity relationship studies[J]. J Med Chem, 2016,59(18):8412-8421. doi: 10.1021/acs.jmedchem.6b00781 URL pmid: 27526615
[50]	Jeanne A, Boulagnon-Rombi C, Devy J , et al. Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide[J]. Clin Exp Meta-stasis, 2016,33(7):637-649. doi: 10.1007/s10585-016-9803-0 URL pmid: 27349907
[51]	Chawla A . Regulation of anti-angiogenicpedf through a tsp-1-cd36 pathway in prostate cancer[J/OL]. Disser Theses-Gradwork, 2013: 672[2017-12-27]. .
[52]	Streit M, Velasco P, Brown LF , et al. Over expression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous cell carcinomas[J]. Am J Pathol, 1999,155:441-452. doi: 10.1016/S0002-9440(10)65140-1 URL pmid: 10433937
[53]	Lindner DJ, Wu Y, Haney R , et al. Thrombospondin-1 expres-sion in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis[J]. Matrix Biol, 2013,32(2):123-132. doi: 10.1016/j.matbio.2012.11.010 URL pmid: 3615071
[54]	Ferdous T, Harada K, Kin T , et al. Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells[J]. Int J Oncol, 2013,43(1):271-279. doi: 10.3892/ijo.2013.1950 URL pmid: 23695365
[55]	Isenberg JS, Ridnour LA, Perruccio EM , et al. Thrombos-pondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner[J]. Proceed Natl Acad Sci, 2005,102(37):13141-13146. doi: 10.1073/pnas.0502977102 URL
[56]	Miao WM, Seng WL, Duquette M , et al. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms[J]. Cancer Res, 2001,61(21):7830-7839. doi: 10.1046/j.1523-5394.2001.96003.x URL pmid: 11691800
[57]	Rofstad EK, Henriksen K, Galappathi K , et al. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts[J]. Cancer Res, 2003,63(14):4055-4061. doi: 10.1016/S0165-4608(03)00013-X URL pmid: 12874006
[58]	Jeanne A, Schneider C, Martiny L , et al. Original insights on thrombospondin-1-related antireceptor strategies in cancer[J]. Front Pharmacol, 2015,6:252. doi: 10.3389/fphar.2015.00252 URL pmid: 4625054